Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017 [J]. CA Cancer J Clin, 2017, 67(1): 7-30 [2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2): 115-132 [3] Marmol I, Sanchez-de-Diego C, Pradilla Dieste A, et al. Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer [J]. Int J Mol Sci, 2017, 18(1).pii: E197 [4] Zhang Y, Chen Z, Li J. The current status of treatment for colorectal cancer in China: A systematic review [J]. Medicine (Baltimore), 2017, 96(40): e8242 [5] Vassilev A, DePamphilis ML. Links between DNA Replication, Stem Cells and Cancer [J]. Genes(Basel), 2017, 8(2).pii: E45 [6] Kar S. Unraveling Cell-Cycle Dynamics in Cancer [J]. Cell Syst, 2016, 2(1): 8-10 [7] Williams GH, Stoeber K. The cell cycle and cancer [J]. J Pathol, 2012, 226(2): 352-364 [8] Poleshko A, Mansfield KM, Burlingame CC, et al. The human protein PRR14 tethers heterochromatin to the nuclear lamina during interphase and mitotic exit [J]. Cell Rep, 2013, 5(2): 292-301 [9] Poleshko A, Katz RA. Specifying peripheral heterochromatin during nuclear lamina reassembly [J]. Nucleus, 2014, 5(1): 32-39 [10] Yang M, Yuan ZM. A novel role of PRR14 in the regulation of skeletal myogenesis [J]. Cell Death Dis, 2015, 6: e1734 [11] Yang M, Lewinska M, Fan X, et al. PRR14 is a novel activator of the PI3K pathway promoting lung carcinogenesis [J]. Oncogene, 2016, 35(42): 5527-5538 [12] Xiao S, Yang M. Discovery of a novel target for cancer: PRR14 [J]. Cell Death Dis, 2016, 7(12): e2502 [13] Yu H, Zhou P, Li D, et al. PRR14 is an independent predictor of poor prognosis in resected non-small cell lung cancer patients [J]. Int J Clin Exp Pathol, 2017, 10(6): 6735-6742 [14] Yang M, Long MJ, Shi XL, et al. PRR14, a novel regulator of Ras signaling pathway [C]. AACR Annual Meeting 2017. Cancer Research, 2017 [15] Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms [J]. Oncogene, 2009, 28(33): 2925-2939 [16] Champeris Tsaniras S, Kanellakis N, Symeonidou IE, et al. Licensing of DNA replication, cancer, pluripotency and differentiation: an interlinked world? [J]. Semin Cell Dev Biol, 2014, 30: 174-180 [17] Mughal MJ, Mahadevappa R, Kwok HF. DNA replication licensing proteins: Saints and sinners in cancer [J]. Semin Cancer Biol, 2019, 58: 11-21 [18] Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy [J]. Nat Rev Cancer, 2008, 8(4): 253-267 [19] Moller MB. P27 in cell cycle control and cancer [J]. Leuk Lymphoma, 2000, 39(1-2): 19-27 [20] Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities [J]. Nat Rev Cancer, 2009, 9(6): 400-414 [21] Karimian A, Ahmadi Y, Yousefi B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage [J]. DNA Repair (Amst), 2016, 42: 63-71
